GigaMune
Cell therapy without the cells.
- Headquarters
- San Francisco, California
- Employees
- 1–10
- Business Model
- B2B
- Website
- gigamune.com
- Last Round
- Pre-SeedMay 2023
- Rounds
- 1
About
GigaMune is a San Francisco-based biotechnology company developing in vivo cell therapies for cancer and inherited blood disorders. The company uses powerful bioinformatics algorithms and high-throughput genomics to design viral gene delivery vectors that target T cells directly inside patients, bypassing the costly manufacturing bottleneck of traditional ex vivo CAR-T cell therapy. GigaMune's pipeline targets multiple myeloma, acute myeloid leukemia (AML), and sickle cell disease, and has received multiple SBIR grants from the NIH.
Summary
GigaMune is a Biotech company based in San Francisco, United States. Its most recent funding was a Pre-Seed round in May 2023. Investors include Boost VC, Sand Hill Angels and Reinforced Ventures.
Tech & App Stack
3 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
May 2023
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/gigamune"><img src="https://indexed.vc/api/badge/company/gigamune" alt="GigaMune on Indexed.vc" width="260" height="76" /></a>